Kai L, Jia L, Zhi-Gang W, Lei Y
Department of Ultrasound Imaging, Huangshi Central Hospital, Hubei Province 435000, PR, China.
Indian J Cancer. 2015 Dec;52 Suppl 2:e102-4. doi: 10.4103/0019-509X.172503.
The aim of this retrospective study was to evaluate whether radiofrequency ablation (RFA) combined percutaneous ethanol injection (PEI) in the management of hepatocellular carcinoma (HCC) improves treatment outcomes.
We retrospectively included 66 HCC patients who received RFA or RFA plus PEI from February 2011 to January 2014 in Jingmen No. 1 People's Hospital. Moreover, 31 cases received RFA plus PEI as the experiment group and 35 subjects treated with RFA aloe as the control group. The overall survival and treatment related complications were compared between the two groups.
For RFA group, the 1-year, 2-year, and 3-year survival rate were 82.0%, 69.3%, and 30.7%, respectively, with the median survival time of 27.1 months. For RFA plus PEI group, the 1-year, 2-year, and 3-year survival rate were 97.1%, 73.9%, and 37.5%, respectively, with the median survival time of 33.6 months. The overall survival of the two groups was not statistical different with the hazard ratio of 1.48 (P > 0.05); three cases of treatment associated complications were found in RFA group with 1 abscess, 1 pleural effusion, and 1 portal vein thrombosis. Moreover, 2 cases of complication were recorded in RFA plus PEI group with 1 pleural effusion and 1 portal vein thrombosis. The complicated incidence rate was not statistical different between the two groups (P < 0.05).
The combination treatment of HCC was safe and had a slightly higher primary effectiveness rate than RFA alone.
本回顾性研究旨在评估射频消融（RFA）联合经皮乙醇注射（PEI）治疗肝细胞癌（HCC）是否能改善治疗效果。
我们回顾性纳入了2011年2月至2014年1月在荆门市第一人民医院接受RFA或RFA联合PEI治疗的66例HCC患者。其中，31例接受RFA联合PEI作为实验组，35例接受单纯RFA治疗作为对照组。比较两组的总生存率和治疗相关并发症。
RFA组1年、2年和3年生存率分别为82.0%、69.3%和30.7%，中位生存时间为27.1个月。RFA联合PEI组1年、2年和3年生存率分别为97.1%、73.9%和37.5%，中位生存时间为33.6个月。两组总生存率无统计学差异，风险比为1.48（P>0.05）；RFA组发现3例治疗相关并发症，包括1例脓肿、1例胸腔积液和1例门静脉血栓形成。此外，RFA联合PEI组记录到2例并发症，包括1例胸腔积液和1例门静脉血栓形成。两组并发症发生率无统计学差异（P<0.05）。
HCC联合治疗安全，初步有效率略高于单纯RFA。
